Pharmafile Logo
Pharmafocus logo
Advanced Search
mehwish_abdeali

Wave appoints Mehwish Abdeali as senior programme executive

September 8, 2015
Medical Communications Mehwish Abdeali, wave

Mehwish Abdeali has been appointed as senior programme executive at Wave, a specialist medical education company. Mehwish joins Wave from …

Appointment
ABPI image

ABPI ‘deeply concerned’ by slow UK drugs uptake

September 7, 2015
Sales and Marketing ABPI, PPRS, Pharmaceutical Price Regulation Scheme, drugs bill, market access, medicines bill

The UK pharma industry paid £209 million to underwrite the UK medicines bill in second quarter of 2015, according to …

News
keytruda

NICE recommends Keytruda for advanced skin cancer

September 7, 2015
Research and Development, Sales and Marketing Merck, NICE, keytruda, skin cancer

NICE has approved Merck’s Keytruda (pembrolizumab) as a treatment for advanced skin cancer in final draft guidance for the NHS.  …

News
healthcareusnow

Pharma industry to deliver strong growth – despite price pressure

September 7, 2015
Sales and Marketing Moody's, financial ratings, industry, industry growth, pharma, pharma industry

The global pharma industry will buck the trend of growing pricing pressure and deliver strong growth in profits, according to a …

News
neuron

Neurology comes to the fore

September 7, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Alzheimer's disease, multiple sclerosis, neurology

Neurology is an area where pharma has struggled to deliver in recent years.Yet the high unmet need for drugs to …

Feature
revlimid_celgene

Celgene threatens to scale back UK clinical trial investment after CDF snub

September 4, 2015
Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, Celgene, Revlimid, british nhs

One of the world’s leading pharma companies in oncology is considering whether to continue investing in clinical trials in the …

News
pfizer_hq_new_york

Pfizer completes $15 billion Hospira acquisition

September 4, 2015
Biosimilar Drugs, Hospira, Pfizer, mergers and acquisitions

Pfizer has completed its acquisition of Illinois-based injectable drugs and infusion device specialist Hospira for around $15 billion.The deal, first announced …

News

Genentech Haemophilia therapy gets FDA breakthrough designation

September 4, 2015
Research and Development, Sales and Marketing Genentech, Roche, haemophilia a

Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …

News
NHS sign

Companies braced for new round of cancer cuts

September 4, 2015
Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NHS England, cuts

Several treatments that extend the lives of people with cancer are expected to be removed from the Cancer Drugs Fund …

News
Farydak

Novartis blood cancer drug Farydak receives EU approval

September 4, 2015
Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat

The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …

News
AstraZeneca plaque

AstraZeneca lung cancer drug clears UK market access hurdle

September 4, 2015
Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer

Follow @Pharmafocus

News
Entresto

Novartis heart failure drug available via EAMS

September 3, 2015
Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan

Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …

News
laptop stethoscope

Health ministers vow NHS tech revolution

September 3, 2015
Medical Communications Jeremy Hunt, NHS, data protection, digital technology, george freeman

UK health ministers have challenged the NHS to fully utilise technology, to empower patients to manage their own healthcare needs.Their …

News
cells

How ‘deep reading’ of the scientific literature will benefit pharma

September 3, 2015
Research and Development Big Data, Cancer, Data Mining, R&D, literature search, oncology

The US Defense Advanced Research Projects Agency (DARPA)’s $45 million ‘Big Mechanism’ initiative has an ambitious aim.It promises to “leapfrog …

Feature

NICE pushes biosimilars in rheumatoid arthritis guidance

September 3, 2015
Sales and Marketing

NICE has published final draft guidance confirming its recommended treatment options for rheumatoid arthritis.  For the first time copycat, or …

News
zarxio

Sandoz launches first US biosimilar

September 3, 2015
Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim

Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …

News
dun___bradstreet_4efa511357b57

Shire appoints Sara Mathew to board of directors

September 2, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Sara Mathew, Shire

Shire has appointed Sara Mathew to its board of directors as a non-executive director.Mathew will also be a member of …

Appointment
CEP report

Pharma ‘spends €40m to sway EU politicians’

September 2, 2015
Medical Communications EU, European Commission, TTIP, drug policy, lobbying, transparency

The pharma industry has excessive power over EU decision-makers and spends €40 million a year to influence EU drug policy, …

News
Alzheimer's brain

Amgen and Novartis partner on Alzheimer’s and migraine treatments

September 2, 2015
Research and Development Alzheimer's disease, Amgen, Novartis, migraine, neurology, neuroscience

Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine.  The companies plan …

News
Novartis image

Two Novartis drugs get first in class EU approvals

September 2, 2015
Research and Development, Sales and Marketing Novartis

The European Commission has approved Revolade for severe aplastic anaemia, and the combination of Tafinlar and Mekinist for patients with …

News
The Gateway to Local Adoption Series

Latest content

Study explores genomic testing approach for unexplained infertility

May 14, 2026

Celtic Renewables receives £7m to develop bio-based solvents

May 14, 2026

Synnovis and SOPHiA GENETICS expand liquid biopsy testing in NHS cancer care

May 13, 2026

MHRA to establish Northern Ireland hub for life sciences sector

May 13, 2026

Shilpa Medicare signs manufacturing deal with NXI Therapeutics

May 12, 2026